XML 22 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Note 7 - Commitments and Contingencies
6 Months Ended
Jun. 30, 2018
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]
Note 
7
– Commitments and Contingencies
 
As of the Effective Date, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with certain accredited investors who acquired common shares in accordance with the Plan of Reorganization (the “Recapitalization Investors”).  The Registration Rights Agreement provides certain resale registration rights to the Recapitalization Investors with respect to the common shares they received.  Pursuant to the Registration Rights Agreement, the Company filed, and has to update periodically, a registration statement with the U.S. Securities and Exchange Commission that covers the resale of all shares of common stock issued to the Investors on the Effective Date until such time as such shares have been sold or
may
be sold without registration or restriction pursuant to Rule
144
under the Securities Act, subject to the Company's ability to suspend sales under the registration statement in certain circumstances. As the Company does
not
qualify for forward incorporation by reference, the Company has caused the suspension of sales under the registration statement pending the filing and effectiveness of a post-effective amendment containing updated financial information.
 
Our primary office and warehouse facilities are located in Gaithersburg, Maryland, and comprise approximately
12,000
square feet. The facilities fall under
two
leases with monthly rent, including our share of certain annual operating costs and taxes, at approximately
$18,000
in total per month and expiring in
September 2019.
In addition, we subleased an approximately
2,100
square foot facility in Nashville, Tennessee, which was utilized as a commercial operations office. The sublease was approximately
$4,000
per month excluding our share of annual operating expenses, and was due to expire
April 
30,
2018.
Effective
January 28, 2018,
we executed a sublease termination agreement which terminated our obligations remaining on the sublease in exchange for our forfeiture of the approximately
$4,000
security deposit on the sublease. We also lease a
16,300
square foot facility located in Durham, North Carolina. Monthly rent, including our share of certain annual operating costs and taxes, is approximately
$22,000
per month and the lease expires on
December 31, 2018.
As a result of our discontinuance of the ALD-
401
clinical trial, the Company ceased use of the facility in Durham, North Carolina on
July 31, 2014,
and sublet the facility beginning
August 1, 2014.
The sublease rent is approximately
$14,000
per month and also expires
December 31, 2018.
Due to non-payment on the lease subsequent to
December 31, 2017,
we were in default on the lease since year end. Effective
June 29, 2018,
we executed a lease termination agreement which terminated all of our remaining financial obligations under the lease in exchange for release of the approximately
$32,000
security deposit on the lease and a
one
-time payment of
$26,000
which was paid on
July 3, 2018.